Dr. Freda Lewis-Hall is the chief medical officer at Pfizer and one of the company's most recognized ambassadors. She's an outspoken advocate for Pfizer and the pharma industry in general, a champion of patient empowerment and a TV medical advice star. FiercePharmaMarketing recently conducted an email interview with the psychiatrist, who also serves by Obama administration appointment to the Board of Governors for the Patient-Centered Outcomes Research Institute (PCORI).
Throughout the tough times faced by the British biopharma industry, the country could always point to its scientific excellence as a source of pride. Now, with more money swilling around, the sector should be enjoying better days, yet as financial woes have receded another resource shortage has come into view: The United Kingdom appears to be running low on scientists.
Kitov Pharma is looking to a Nasdaq IPO to fund the final steps in development of its osteoarthritis drug. The product, which is already deep into Phase III, is a combination of Pfizer's Celebrex and an antihypertensive drug, a mix Kitov thinks will enable it to avoid the black-box warnings that blight other treatments for osteoarthritis.
Brent Saunders has vaulted from Bausch & Lomb to Forest Labs and then on to the helm of a rapidly evolving Allergan. And with Allergan now in amiable discussions for a megamerger with Pfizer, the management team quarterback clearly has his sights set on the big prize: CEO of a greatly expanded pharma giant.
Pfizer and Allergan are currently in "friendly" merger talks. And if they do tie the knot, it's looking like Allergan CEO Brent Saunders will take the helm.
Pfizer is recalling thousands of bottles of its anxiety drug Xanax, saying the drug may not be strong enough.
How big is Pfizer's "tremendous disadvantage" from its U.S. tax rate? Bigger when you report your foreign earnings the way the pharma giant does. Pfizer told shareholders it had a 25.5% global tax rate in 2014, but had it reported its foreign earnings the way most U.S. companies do, that figure could have dropped to 7.5%, The Wall Street Journal reports.
Allergan CEO Brent Saunders, who once called Big Pharma's perceived need for drug discovery "a fallacy," has come around on early-stage research, a change in tone that happens to coincide with Pfizer's stated interest in buying his company.
Big Pharma Allergan announced it is bulking up in aesthetics by purchasing London's Northwood Medical Innovation, maker of the earFold device for the correction of prominent ears, with or without asymmetry, in patients 7 or older. The deal marks the third Allergan device deal in recent months.
Like the rest of Big Pharma over the past couple of months, Pfizer has been defending its U.S. drug prices against unprecedented criticism. CEO Ian Read recently pointed the finger at insurance companies that are using high deductibles, coinsurance and copays to limit their own spending and boost their bottom lines.